Literature DB >> 8739847

Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports.

J Staedt1, G Stoppe, H Riemann, G Hajak, E Rüther, P Riederer.   

Abstract

In previous investigations we found an increase of D2 dopamine receptors in the striatum of patients with nocturnal myoclonus syndrome (NMS) after treatment with dopamimetics. Under the hypothesis, that, according to animal experiments, the glutamatergic system could be involved in this atypical dopaminergic up-regulation in NMS. The glutamate release inhibitor lamotrigine was tested in up to now two NMS patients. The results and the success of this approach and its implications are discussed.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8739847     DOI： 10.1007/BF01271247

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  19 in total

1.  Cluster arousal analysis in chronic pain-disturbed sleep.

Authors: 
Journal:  J Sleep Res       Date:  1993-09       Impact factor: 3.981

2.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

Review 3.  Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia.

Authors:  A A Grace
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

Review 4.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

5.  Cerebral decortication reverses the effect of amphetamine on striatal D2 dopamine binding site density.

Authors:  H A Robertson
Journal:  Neurosci Lett       Date:  1986-12-23       Impact factor: 3.046

6.  Dopamine release in the nucleus caudatus and in the nucleus accumbens is under glutamatergic control through non-NMDA receptors: a study in freely-moving rats.

Authors:  A Imperato; T Honoré; L H Jensen
Journal:  Brain Res       Date:  1990-10-22       Impact factor: 3.252

7.  Lamotrigine--antiparkinsonian activity by blockade of glutamate release?

Authors:  F Zipp; H Baas; P A Fischer
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1993

Review 8.  Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.

Authors:  J T Greenamyre
Journal:  J Neural Transm Gen Sect       Date:  1993

9.  Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).

Authors:  J Staedt; G Stoppe; A Kögler; H Riemann; G Hajak; D L Munz; D Emrich; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1995

10.  Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration.

Authors:  J Staedt; G Stoppe; A Kögler; H Riemann; G Hajak; D L Munz; D Emrich; E Rüther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270
View more
  2 in total

1.  Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Authors:  J Staedt; F Wassmuth; U Ziemann; G Hajak; E Rüther; G Stoppe
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 2.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.